NCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
Clinical Trials
34 trialsNCT02099058 2025-08-14
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
AbbVie
Phase 1 Active not recruiting
NCT04341181 2025-07-25
ProTarget
Rigshospitalet, Denmark
Phase 2 Recruiting
NCT06161558 2025-07-16
Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT01010945 2024-11-21
Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
Astellas Pharma Inc
Phase 1 Completed
NCT02942095 2023-04-18
Study of Ixazomib and Erlotinib in Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03239015 2022-03-04
Efficacy and Safety of Precision Therapy in Refractory Tumor
Shanghai Changzheng Hospital
Phase 2 Unknown
NCT01636908 2021-04-15
ICK
Amsterdam UMC, location VUmc
Phase NA Completed
NCT02714530 2021-03-30
ThoRaT
Oslo University Hospital
Phase 2 Terminated
NCT01197170 2021-01-22
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01190241 2020-11-20
TSAP
Amsterdam UMC, location VUmc
Phase NA Terminated
NCT00848718 2019-11-12
MK-2206-003
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01518621 2019-03-13
RadEr
Oslo University Hospital
Phase 2 Terminated
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT01376310 2019-02-19
GSK1120212 Rollover Study
Novartis
Phase 2 Terminated
NCT01284335 2019-01-10
A Safety Study in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT00954512 2018-08-24
Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT01472016 2017-11-21
Study of ABT-700 in Subjects With Advanced Solid Tumors
AbbVie
Phase 1 Completed
NCT01192165 2017-11-13
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
GlaxoSmithKline
Phase 1 Completed
NCT00369512 2017-05-30
RAD0503
University of Alabama at Birmingham
Phase 2 Completed
NCT01482377 2017-01-27
A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin
Hoffmann-La Roche
Phase 1 Completed
NCT00811993 2016-11-02
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated
NCT00737243 2016-08-17
Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00207077 2015-10-28
Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors
Eli Lilly and Company
Phase 1 Completed
NCT00585377 2015-09-24
Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer
University of Utah
Phase 2 Completed
NCT01009203 2015-08-10
Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00895687 2015-07-13
Study of Erlotinib in Combination With Bortezomib
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00903734 2015-07-13
An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00476476 2015-05-07
Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01727869 2015-04-06
Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
Regeneron Pharmaceuticals
Phase 1 Completed
NCT00884845 2014-03-26
Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
PharmaMar
Phase 1 Completed
NCT00360360 2013-12-04
Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Carcinoma of Unknown Primary Site
SCRI Development Innovations, LLC
Phase 2 Completed
NCT00591383 2012-07-19
Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors
Alaunos Therapeutics
Phase 1 Unknown
NCT00611468 2011-08-22
Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors
Accelerated Community Oncology Research Network
Phase 1 Completed